Showing results (61-70 of 504) with videos related to
Sort By:
Pageof 51
Journal of Hematology & Oncology|January 13, 2017
Is CD47 an innate immune checkpoint for tumor evasion?Xiaojuan Liu, Hyunwoo Kwon, Zihai Li, et al.Cytotechnology|December 18, 2014
Immunobiology and signaling pathways of cancer stem cells: implication for cancer therapyMohamed L Salem, Ahmed S El-Badawy, Zihai LiBladder Cancer (Amsterdam, Netherlands)|October 24, 2022
Mechanism of Sex Differences in Bladder Cancer: Evident and Elusive Sex-biasing FactorsChrista M Lam, Zihai Li, Dan Theodorescu, et al.Journal of Hematology & Oncology|April 14, 2016
Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancerShuhang Wang, Shundong Cang, Delong LiuBiomarker Research|April 24, 2019
Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphomaAmandeep Aujla, Ravijot Aujla, Delong LiuBiomarker Research|September 19, 2019
Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemiaJuanjuan Zhao, Yongping Song, Delong LiuJournal of Hematology & Oncology|November 27, 2010
First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinibGuoqing Wei, Shamudheen Rafiyath, Delong LiuTransfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|November 16, 2010
T-cryptantigen (TCA) activation in sever pneumonia complicated with multiple organ failureQiushi Wang, Delong Liu, Yingzhe BaiExperimental Hematology & Oncology|December 6, 2012
CD19: a biomarker for B cell development, lymphoma diagnosis and therapyKemeng Wang, Guoqing Wei, Delong LiuJournal of Hematology & Oncology|June 7, 2026
Novel BTK inhibitors and degraders for relapsed/refractory CLL/SLL: latest updates from ASH 2025 annual meetingPritika Sharma, Heng Jiang, Delong LiuPageof 51